Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02010710
Other study ID # 06/38/01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 6, 2010
Est. completion date May 2014

Study information

Verified date October 2018
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In women judged to require continuous electronic fetal heart rate monitoring (EFM) during their labour, does the addition of decision support software to aid the interpretation of the intrapartum cardiotocogram (CTG) reduce the number of 'poor neonatal outcomes'? This study is not introducing a new form of labour monitoring; it is evaluating the addition of decision-support to CTGs displayed on the Guardian™ system. Specifically comparing: "No decision-support" - CTGs with no additional interpretation (UK standard care), compared with: "Decision-support" - CTGs with the decision support software running that will alert clinicians to the presence of abnormalities in the CTG in real time. How the labour is managed is entirely up to the recruiting unit and the woman; however the allocation of decision-support or no decision-support is determined randomly by the Guardian™ system.


Recruitment information / eligibility

Status Completed
Enrollment 47062
Est. completion date May 2014
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Female
Age group 16 Years and older
Eligibility Inclusion Criteria:

- Require continuous electronical fetal monitoring during labour

- they have a singleton or twin pregnancy

- they are = 35 weeks' gestation (= 245 days)

- there is no known gross fetal abnormality, including any known fetal heart arrhythmia such as heart block

- they are 16 years of age or older

- they are able to give consent to participate in the trial as judged by the attending clinicians.

Exclusion Criteria:

- • triplets or higher order pregnancy

- criteria for EFM not met, including elective caesarean section prior to the onset of labour

Study Design


Related Conditions & MeSH terms

  • Fetal Intrauterine Distress First Noted During Labor and or Delivery in Liveborn Infant
  • Possible
  • Team Based on Their Existing Guidelines and the Woman Consents to Have EFM and EFM is

Intervention

Device:
INFANT software
The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.

Locations

Country Name City State
Ireland Rotunda Dublin
United Kingdom Birmingham Women's Hospital Birmingham
United Kingdom Royal Bolton Hospital Bolton
United Kingdom Lancashire Women's and Newborn Centre Burnley Lancs
United Kingdom University Hospitals Coventry & Warwick Coventry
United Kingdom Royal Derby Hospital Derby
United Kingdom Princess Royal Glasgow
United Kingdom Southern General Glasgow
United Kingdom Liverpool Women's Hospital Liverpool
United Kingdom Chelsea and Westminster Hospital London
United Kingdom Homerton University Hospital London
United Kingdom Northwick Park Hospital London
United Kingdom St Mary's Hospital Manchester
United Kingdom Nottingham City/Queens Medical Centre Nottingham
United Kingdom Derriford Hospital Plymouth
United Kingdom Queen Alexandra Portsmouth
United Kingdom Princess Anne Southampton
United Kingdom Stoke Mandeville Hospital Stoke Mandeville
United Kingdom University Hospital North Staffs Stoke-on-Trent
United Kingdom Warrington Hospital Warrington
United Kingdom Warwick Hospital Warwick

Sponsors (7)

Lead Sponsor Collaborator
University College, London K2 Medical Systems, National Childbirth Trust, University of Birmingham, University of Leicester, University of Oxford, University of Plymouth

Countries where clinical trial is conducted

Ireland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Infant outcomes Metabolic acidosis defined as a cord-artery pH <7.05 (this is 2 standard deviations below the mean) with base deficit = 12 mmol/l (this is a threshold above which the risks of neurological damage increase)
The distribution of cord-blood gas data for cord-artery pH
Apgar score <4 at 5 minutes
Intrapartum stillbirth
Neonatal death
Seizures
Resuscitation interventions
Admissions to neonatal unit within 48 hours of birth for at least 48 hours
Admissions to neonatal unit within 48 hours of birth for at least 48 hours with evidence of:
Encephalopathy
Feeding difficulties
Respiratory illness
Admission to a higher level of care
In the sub-set of 7,000 surviving children without any degree of encephalopathy and agreed to be followed-up at age 2 years:
PARCA-R composite score
Cerebral palsy - (determined by asking the parents if their child has Cerebral palsy)
Late deaths (after the neonatal period)
General health issues at 2 years
during admission and at 2 years
Other Mother Mode of delivery
Any operative intervention (caesarean section and instrumental delivery) for i. fetal distress, or ii. failure to progress, or iii. combination of fetal distress and failure to progress iv. other reason
Any episode of fetal blood sampling
Episiotomy
Grade of caesarean section
Length of first stage, length of second stage, total length of labour from trial entry
during admission
Primary Admissions to higher level of care A composite of 'poor perinatal outcome' to include (a) all deaths (intrapartum stillbirths plus neonatal deaths i.e. deaths up to 28 days after birth) except deaths due to congenital anomalies, (b) significant morbidity: neonatal encephalopathy (moderate and severe); (c) admissions to the neonatal unit within 48 hours of birth for = 48 hrs with evidence of feeding difficulties, respiratory illness or encephalopathy. within 48 hours and for longer than 48 hours
Secondary Neuro Development PARCA-R composite score at the age of two years 2 years

External Links